Annals of Vascular Surgery
Издатель: Elsevier · ISSN 0890-5096 · 63 статей
-
Predict. Support. Act? DeepComp and post-operative risk in gastric cancer
Publication date: October 2026 Source: Annals of Oncology, Volume 37, Issue 10 Author(s): A. Rabasco Meneghetti
-
Keeping the story, turning the page: from prognostic to predictive AI in high-risk prostate cancer
Publication date: October 2026 Source: Annals of Oncology, Volume 37, Issue 10 Author(s): S.P. Mende, S. Foersch
-
The return of the adult thymus in radiation oncology?
Publication date: October 2026 Source: Annals of Oncology, Volume 37, Issue 10 Author(s): A. Levy, D. Morel, L. Meziani, M. Mondini, A. Shrebati, A. Botticella, C. Le Péchoux, C. Robert, E. Deutsch
-
HER2-directed TAC T cells in solid tumors: a step forward, but not yet a therapeutic leap
Publication date: October 2026 Source: Annals of Oncology, Volume 37, Issue 10 Author(s): M. Pedregal, V. Moreno
-
Next-generation sequencing consensus guidelines for sarcoma: progress, gaps, and the path forward
Publication date: October 2026 Source: Annals of Oncology, Volume 37, Issue 10 Author(s): V. Subbiah, R. Kurzrock
-
Multimodal artificial intelligence prediction of abiraterone efficacy in two STAMPEDE phase III trials of nonmetastatic very high-risk prostate cancer ☆
Publication date: October 2026 Source: Annals of Oncology, Volume 37, Issue 10 Author(s): C.T.A. Parker, H-C. Huang, E. Grist, L. Mendes, R. Yamashita, D. Croucher, A. Sachdeva, L. Murphy, V.Y.T. Liu, S. Santos Vidal, T. Todorovic, S....
-
Thymic radiation is associated with worse outcomes in patients with NSCLC
Publication date: October 2026 Source: Annals of Oncology, Volume 37, Issue 10 Author(s): V. Prudente, S. Bernatz, S. Pai, K.M. Atkins, F. Pecci, E. Garbo, K. Bressem, C.V. Guthier, A. Warrington, M. Tonneau, C. Ciausu, S. Yu, L....
-
Autologous T-cell antigen coupler targeting HER2 (TAC01-HER2) in advanced or metastatic solid tumors
Publication date: October 2026 Source: Annals of Oncology, Volume 37, Issue 10 Author(s): E.E. Dumbrava, D. Olson, M.A. Gouda, M.A. George, S.D. Saibil, M. Apostolopoulou, M. Bishop, M.N. Gavriliuc, A.M. Kennon, J.A. Weiss, C. Ayers, K....
-
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer ☆
Publication date: October 2026 Source: Annals of Oncology, Volume 37, Issue 10 Author(s): P.A. Francis, O. Pagani, G.F. Fleming, B.A. Walley, M. Colleoni, G. Rubovszky, C. Tondini, E.M. Ciruelos, H.L. Gomez, H.R. Bonnefoi, H.J....
-
A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial
Publication date: October 2026 Source: Annals of Oncology, Volume 37, Issue 10 Author(s): G.M. Kim, K.H. Jung, H.C. Jeung, J. Lee, K.S. Lee, S.A. Im, S.Y. Kang, S.H. Kim, H.J. Kim, K.H. Park, Y.S. Chae, S.J. Koh, E.K. Cho, K.U. Park,...
-
SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer ☆
Publication date: October 2026 Source: Annals of Oncology, Volume 37, Issue 10 Author(s): A.C. Garrido-Castro, S.E. Kim, T. Li, J. Desrosiers, R. Nanda, Y. Abdou, A.S. Clark, R.L. Sacks, T. O’Connor, N. Sinclair, S. Lo, G. Augdahl, E....
-
Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial
Publication date: October 2026 Source: Annals of Oncology, Volume 37, Issue 10 Author(s): F. Han, Y.Q. Xiang, X.H. Wang, S. Qu, L.Q. Tang, X.L. Shu, P. Zhang, S.F. Qiu, Y.J. Zhou, Y. Guo, G.Q. Xu, Q. Li, K.Y. Yang, Y.Q. Du, M.J. Xu,...
-
A multimodal deep learning model for preoperative prediction of post-operative complications in gastric cancer
Publication date: October 2026 Source: Annals of Oncology, Volume 37, Issue 10 Author(s): P.A. Ding, S. Yang, L.J. Meng, S. Chen, S.P. Li, H.H. Guo, J.X. Yang, S. Ma, Y.H. Yang, K.X. Gao, R.J. Gu, L.L. Zhang, Y.L. Chen, Y.L. Shi, H....
-
Prompt-directed ambient artificial intelligence for automated multidisciplinary tumor board documentation
Publication date: October 2026 Source: Annals of Oncology, Volume 37, Issue 10 Author(s): R. Philips, A. Mahajan, L. Estephan, S. Auger, W. Haque, D. Palmer, J. McQueen, E. MacCracken, P.P. Argyris, A. Trzcinska, N.A. Cipriani, M....
-
Reply to “Next-generation sequencing consensus guidelines for sarcoma: progress, gaps, and the path forward”
Publication date: October 2026 Source: Annals of Oncology, Volume 37, Issue 10 Author(s): C. Serrano, J.Y. Blay, J.V.M.G. Bovée
-
The ethical obligation to use positive trial results
Publication date: October 2026 Source: Annals of Oncology, Volume 37, Issue 10 Author(s): J.-Y. Blay, D. Perol
-
Corrigendum to “Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER)”: [Annals of Oncology 37 (2026) 1220-1229]
Publication date: Available online 20 October 2026 Source: Annals of Oncology Author(s): K. Kalinsky, W.E. Barlow, H.B. Pathak, R.V. Puri, A. Mitra, T. Home, J. Gralow, K.S. Albain, D.F. Hayes, S. Delaloge, N.U. Lin, E.A. Perez, L.J....
-
The ESMO Scale for Clinical Actionability of Molecular Targets, version 2 (ESCAT v2): an evidence-based framework for ranking alterations as actionability and resistance biomarkers in precision oncology
Publication date: Available online 21 October 2026 Source: Annals of Oncology Author(s): A. El Helali, C. Cardone, N. Coleman, J.R. Beal, M.V. Cruz-Ordinario, E. Kocakavuk, M. K-l. Chiu, D. Thomas, C. Turnbull, F. Meric-Bernstam, M.F....
-
Active surveillance versus standard surgery after neoadjuvant chemoradiotherapy for oesophageal cancer: long-term results of a cluster-randomised controlled trial (SANO)
Publication date: Available online 23 October 2026 Source: Annals of Oncology Author(s): S.S.G. Gangaram Panday, B.J. van der Wilk, S.M. Lagarde, B.M. Eyck, C. Rosman, B.J. Noordman, M.J. Valkema, T.M. Bisseling, P.P.L.O. Coene, M.J....
-
Perioperative pembrolizumab or placebo plus neoadjuvant cisplatin and gemcitabine in participants with muscle-invasive bladder cancer who are eligible for cisplatin: the double-blind, phase III KEYNOTE-866 study
Publication date: Available online 23 October 2026 Source: Annals of Oncology Author(s): J. Bedke, P. Arkosy, H. Nishiyama, H. Mahammedi, C. Vulsteke, M.J. Juan-Fita, I. Antonyan, O. Didas, E. Verzoni, V. Atduev, A. Rodriguez-Vida, J.J....
-
Capivasertib plus abiraterone in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer: updated survival analysis from CAPItello-281 ☆
Publication date: Available online 23 October 2026 Source: Annals of Oncology Author(s): K. Fizazi, N.W. Clarke, M. De Santis, H. Uemura, A.P. Fay, N. Karadurmus, C. Alvarez-Fernandez, S. Jiang, D. Parslow, M. Sotelo, Y. Ürün, N....
-
Nivolumab plus relatlimab with platinum-doublet chemotherapy versus nivolumab with platinum-doublet chemotherapy in stage IV or recurrent non-small cell lung cancer: clinical, translational, and patient-reported outcomes results from the phase II RELATIVITY-104 study
Publication date: Available online 23 October 2026 Source: Annals of Oncology Author(s): N. Girard, M. Burotto, L.G. Paz-Ares, M. Schenker, A. Lingua, F. Orlandi, J. Naidoo, E.K. Beardsley, V. Velcheti, G.L. Martinengo, E. Felip, M....
-
Neoadjuvant nivolumab plus gemcitabine–cisplatin followed by postsurgical adjuvant nivolumab versus neoadjuvant gemcitabine–cisplatin in patients with muscle-invasive bladder cancer: final results from the phase III CA017-078 trial ☆
Publication date: Available online 23 October 2026 Source: Annals of Oncology Author(s): G. Sonpavde, M.S. van der Heijden, S. Gupta, M.D. Galsky, G. Steinberg, J.E. Gschwend, J.P. Sade, D. Bimbatti, U. De Giorgi, G. Schepisi, S....
-
Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2– early breast cancer: Six-year follow-up of the NATALEE trial
Publication date: Available online 23 October 2026 Source: Annals of Oncology Author(s): D.J. Slamon, G.N. Hortobagyi, D. Stroyakovskiy, D.A. Yardley, C.-S. Huang, J. Crown, A. Bardia, S. Chia, S.-A. Im, M. Martin, S. Loi, B. Xu, S.A....
-
Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR-positive, HER2-negative advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy ☆
Publication date: Available online 24 October 2026 Source: Annals of Oncology Author(s): K. Kalinsky, S.A. Wander, E. Hamilton, S.L. Graff, R. Jeselsohn, K.H. Park, U. Demirci, M. Martin, R.M. Layman, S.A. Hurvitz, S. Sammons, P.A....
-
Pembrolizumab Plus Chemotherapy for HR+/HER2− PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study
Publication date: Available online 24 October 2026 Source: Annals of Oncology Author(s): H.S. Rugo, M. Kok, A. Goncalves, D. Loirat, G. Bianchini, P.A. Fasching, D.W. Cescon, R. Romero Díaz, F. Zagouri, E. Korbenfeld, F. Dalenc, Y....
-
Atirmociclib and fulvestrant for patients with HR-positive/HER2-negative advanced or metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial ☆
Publication date: Available online 24 October 2026 Source: Annals of Oncology Author(s): A. Giordano, B. Xu, T. Yoshinami, C.-S. Huang, Y.H. Park, G.L. Lerzo, H. Li, A. Shai, G. Garnica Jaliffe, M. Itoh, A. Williams, S. Goel, S.-A. Im,...
-
Adjuvant chemotherapy with cisplatin and gemcitabine compared with standard of care after curative intent resection of cholangiocarcinoma and muscle-invasive gallbladder carcinoma (ACTICCA-1/AIO-HEP-0112 trial) ☆
Publication date: Available online 24 October 2026 Source: Annals of Oncology Author(s): A. Stein, J. Bridgewater, H.-J. Klümpen, T. Gruenberger, J. Shannon, L. Fornaro, L.H. Jensen, D. Arnold, J. Primrose, D. Goldstein, A.W. Lohse, J....
-
A randomized phase I study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine–tipiracil with bevacizumab in patients with metastatic colorectal cancer ☆
Publication date: Available online 24 October 2026 Source: Annals of Oncology Author(s): M. Cecchini, M. Cruz-Correa, S.-W. Han, K. Raghav, A. Landa-Magdalena, J.H. Strickler, A. Calvo, A. Hollebecque, T.E. Nakajima, G. Perl, V. Jain,...
-
Final results of nivolumab plus ipilimumab versus nivolumab or chemotherapy in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW ☆
Publication date: Available online 24 October 2026 Source: Annals of Oncology Author(s): S. Lonardi, H.-J. Lenz, E. Elez, L.H. Jensen, E. Van Cutsem, Y. Touchefeu, R. Garcia-Carbonero, D. Tougeron, G.A. Mendez, M. Schenker, C. de la...